TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
NextCell Pharma AB
Closing information (x1000 SEK)
| Closing information | 2024/08 | 2023/08 | 2022/08 |
| Turnover |
10,665
|
10,113
|
5,589 |
| Financial expenses |
1
|
3
|
14 |
| Earnings before taxes |
-41,960
|
-39,812
|
-34,554 |
| EBITDA |
-42,197
|
-40,554
|
-34,567 |
| Total assets |
81,288
|
88,827
|
124,655 |
| Current assets |
60,625
|
67,273
|
106,755 |
| Current liabilities |
9,873
|
10,080
|
6,932 |
| Equity capital |
67,599
|
75,727
|
115,539 |
| - share capital |
14,984
|
7,048
|
7,048 |
| Employees (average) |
24
|
17
|
15 |
Financial ratios
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Solvency |
83.2%
|
85.3%
|
92.7% |
| Turnover per employee |
444
|
595
|
373 |
| Profit as a percentage of turnover |
-393.4%
|
-393.7%
|
-618.3% |
| Return on assets (ROA) |
-51.6%
|
-44.8%
|
-27.7% |
| Current ratio |
614.0%
|
667.4%
|
1540.0% |
| Return on equity (ROE) |
-62.1%
|
-52.6%
|
-29.9% |
| Change turnover |
552
|
4,524
|
1,677 |
| Change turnover % |
5%
|
81%
|
43% |
| Chg. No. of employees |
7
|
2
|
2 |
| Chg. No. of employees % |
41%
|
13%
|
15% |
Total value of public sale
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.